Thetis Pharmaceuticals LLC
Raised
$560K
Investors
10
Min Invest
None stated
AltStreet Analysis
·Generated from EDGAR primary sources
Thetis Pharmaceuticals LLC, a Connecticut-based pharmaceutical operating company, filed a Form D on 2026-10-13 for a Rule 506(b) private offering of debt securities with an option to acquire equity, reporting $560,000 raised from 10 investors. No minimum investment amount or first sale date is disclosed on the filing. This is an original (non-amendment) filing and does not appear to be part of a known investment platform or fund sponsor group.
This filing reflects a small private debt/convertible-type financing by an operating pharmaceutical issuer rather than a pooled investment fund; the $560K total raise and 10-investor count represent a modest bridge-financing round, well below the scale typical of institutional alternative-investment vehicles filing under 506(b).
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
Fund Family
Every vehicle in this manager's series as it appears on EDGAR, newest generation first. Sold-to-date and investor counts are each vehicle's latest Form D.
Fund family
Thetis Pharmaceuticals1 vehicle · 0 generations · since 2016 · $8.0M sold across the family
| Vehicle | Role | First filed | Status | Sold | Investors |
|---|---|---|---|---|---|
| Unnumbered · first filed 2026-10-13 · 1 vehicle · $560K sold · 10 investors | |||||
| Thetis Pharmaceuticals LLCthis issuer | 2026-10-13 | raising | $560K | 10 | |
Grouped from Form D issuer names (generation, sleeve, jurisdiction and legal-form tokens removed); a name-only match, so abbreviated or renamed vehicles can be missed. Sold and investor figures are each vehicle's latest Form D; sleeves that report the same figure share one family-wide total and are counted once. Performance lines are what a public pension plan reports for its own interest in that fund, net, on the plan's cash flows and valuation date; they are not the general partner's figures.
In the Terminal
Filing events
1
latest Oct 13, 2026
Critical / warning
0 / 0
0 watch · 1 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
5
raising, lapsed
Latest event New filer · Oct 13, 2026
SEC.govInvestor
- 1 filing event with values and deltas, latest 2026-10-13, and alerts on the next one
- 5 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2026-10-13: 2 related persons added and 1 removed against the filing of 2022-07-11; 6 now listed. The names are in the Terminal feed.
Gary Mathias
Executive Officer, Director · Deep River, CT
Walter Ogier
Director · Union Pier, MI
Frank Sciavolino
Director · Quaker Hill, CT
Dennis Willson
Director · Rancho Sante Fe, CA
Fabio Cataldi
Director · Deep River, CT
David Cook
Director · Deep River, CT
Questions About Thetis Pharmaceuticals LLC
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Thetis Pharmaceuticals LLC?
Thetis Pharmaceuticals LLC is a Connecticut limited liability company that filed a Form D with the SEC on October 13, 2026 in the Pharmaceuticals industry group. The filing claims Rule 506(b) for an offering of debt.
Is Thetis Pharmaceuticals LLC legit?
AltStreet does not rate legitimacy; it reports the public record. Thetis Pharmaceuticals LLC filed a Form D with the SEC on October 13, 2026 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $560,300 sold to 10 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Thetis Pharmaceuticals LLC registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Thetis Pharmaceuticals LLC claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Thetis Pharmaceuticals LLC raised?
Thetis Pharmaceuticals LLC reported $560,300 sold from 10 investors of a $1,000,000 total offering as of the Form D filed October 13, 2026.
Who can invest in Thetis Pharmaceuticals LLC?
The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in Thetis Pharmaceuticals LLC?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling Thetis Pharmaceuticals LLC and how are they paid?
The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.
Who is behind Thetis Pharmaceuticals LLC?
The Form D lists 6 related persons: Gary Mathias, executive officer, director (Manager); Walter Ogier, director (Manager); Frank C. Sciavolino, director (Manager); Dennis Willson, director (Manager); Fabio Cataldi, director (Manager); David Cook, director (Manager). Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Thetis Pharmaceuticals LLC located?
The issuer's address on its SEC filings is 80 Meadows Road, Deep River, CT 06417. Its phone number of record is 203-470-7772. It is organized under the laws of Connecticut.
How long is the Thetis Pharmaceuticals LLC offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.
What is Thetis Pharmaceuticals LLC's revenue?
The issuer declined to disclose its revenue range on the Form D, which the form permits.
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.